Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was in line with analysts’ consensus estimates. Is now the time to buy Viatris? Find out in our full research report. Viatris (VTRS) Q1 CY2025 Highlights: Revenue: $3.25 billion vs analyst estimates of $3.28 billion (11.2% year-on-year decline, 0.7% miss) Adjusted EPS: $0.50 vs analyst estimates of $0.49 (in line) Adjusted EBITDA: $923.5 million vs analyst estimates of $903 million (28.4% margin, 2.3% beat) The company reconfirmed its revenue guidance for the full year of $13.75 billion at the midpoint Management raised its full-year Adjusted EPS guidance to $2.23 at the midpoint, a 1.8% increase EBITDA guidance for the full year is $4.04 billion at the midpoint, in line with analyst expectations Operating Margin: -88.6%, down from 5.6% in the same quarter last year Market Capitalization: $10.27 billion Company Overview Created through the 2020 merger of Mylan and Pfizer's Upjohn division, Viatris (NASDAQ:VTRS) is a healthcare company that develops, manufactures, and distributes branded and generic medicines across more than 165 countries worldwide. Sales Growth A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, Viatris grew its sales at a mediocre 4.3% compounded annual growth rate. This was below our standard for the healthcare sector and is a tough starting point for our analysis.Viatris Quarterly Revenue We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Viatris’s performance shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 4.8% annually.Viatris Year-On-Year Revenue Growth This quarter, Viatris missed Wall Street’s estimates and reported a rather uninspiring 11.2% year-on-year revenue decline, generating $3.25 billion of revenue. Looking ahead, sell-side analysts expect revenue to decline by 3.4% over the next 12 months, similar to its two-year rate. Although this projection is better than its two-year trend, it's hard to get excited about a company that is struggling with demand. Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Story Continues Operating Margin Viatris’s high expenses have contributed to an average operating margin of negative 1.2% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle. Looking at the trend in its profitability, Viatris’s operating margin decreased by 16.7 percentage points over the last five years. This performance was caused by more recent speed bumps as the company’s margin fell by 29.7 percentage points on a two-year basis. We’re disappointed in these results because it shows its expenses were rising and it couldn’t pass those costs onto its customers.Viatris Trailing 12-Month Operating Margin (GAAP) This quarter, Viatris generated a negative 88.6% operating margin. The company's consistent lack of profits raise a flag. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable. Sadly for Viatris, its EPS declined by 11.2% annually over the last five years while its revenue grew by 4.3%. This tells us the company became less profitable on a per-share basis as it expanded.Viatris Trailing 12-Month EPS (Non-GAAP) Diving into the nuances of Viatris’s earnings can give us a better understanding of its performance. As we mentioned earlier, Viatris’s operating margin declined by 16.7 percentage points over the last five years. Its share count also grew by 131%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders.Viatris Diluted Shares Outstanding In Q1, Viatris reported EPS at $0.50, down from $0.67 in the same quarter last year. Despite falling year on year, this print beat analysts’ estimates by 1.6%. Over the next 12 months, Wall Street expects Viatris’s full-year EPS of $2.49 to shrink by 7.9%. Key Takeaways from Viatris’s Q1 Results It was good to see Viatris raise its full-year EPS guidance. On the other hand, its revenue and full-year revenue guidance fell slightly short of Wall Street’s estimates. Overall, this quarter could have been better, but the stock traded up 8.4% to $9.32 immediately following the results due to the profit outlook. Should you buy the stock or not? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free. View Comments
Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...